Abstract | PURPOSE: METHODS: Identification of ZYTP1, a novel PARP inhibitor, through a battery of in vitro assays and in vivo studies. PARP and TNKS inhibitory activity of ZYTP1 was assessed in cell-free kinase assay. In vitro cell killing potency of ZYTP1 was tested in a panel of cell lines including BRCA-negative cells. ZYTP1 was also tested in xenograft models in combination with temozolomide (TMZ). The pharmacokinetic profile of ZYTP1 was determined in rodent and non-rodent preclinical species. Safety of ZYTP1 was assessed in Wistar rats and Beagle dogs upon repeated dosing. RESULTS: ZYTP1 inhibited PARP1, PARP2, Tankyrase-1 and Tankyrase-2 with IC50 of 5.4, 0.7, 133.3 and 289.8 nM, respectively, and additionally trapped PARP1 onto damaged DNA. It also potentiated MMS-mediated killing of different cancer cell lines. Compound demonstrated good Caco-2 cell permeability. The oral bioavailability of ZYTP1 in mice, rats and dogs ranged between 40 and 79% and demonstrated efficacy in colon cancer xenograft model at a dose of 1-10 mg/kg in combination with TMZ. In a 28-day repeat dosing, oral toxicity study in rats, it was found to show > 10× safety margin. CONCLUSIONS: ZYTP1 is a novel PARP inhibitor that showed potential for development as a treatment for various solid tumors.
|
Authors | Mukul R Jain, Jogeswar Mohapatra, Debdutta Bandhyopadhyay, Abhijit Chatterjee, Krishnarup Ghoshdastidar, Dinesh Patel, Ankit Patel, Hitesh Bhayani, Brijesh Kumar Srivastava, Sandeep A Shedage, Pravin Kadam, Rajesh Sundar, Harilal Patel, Poonam Giri, Prakash Patel, Laxmikant Gupta, Nuggehally R Srinivas, Pankaj R Patel, Ranjit C Desai |
Journal | Cancer chemotherapy and pharmacology
(Cancer Chemother Pharmacol)
Vol. 82
Issue 4
Pg. 635-647
(10 2018)
ISSN: 1432-0843 [Electronic] Germany |
PMID | 30046848
(Publication Type: Journal Article)
|
Chemical References |
- Poly(ADP-ribose) Polymerase Inhibitors
- Poly(ADP-ribose) Polymerases
- Tankyrases
|
Topics |
- Animals
- Apoptosis
(drug effects)
- Biological Availability
- Breast Neoplasms
(drug therapy)
- Cell Line, Tumor
- Cell Proliferation
(drug effects)
- Colonic Neoplasms
(drug therapy)
- DNA Damage
(drug effects)
- Dogs
- Drug Monitoring
(methods)
- Humans
- Mice
- Poly(ADP-ribose) Polymerase Inhibitors
(pharmacology)
- Poly(ADP-ribose) Polymerases
(metabolism)
- Rats
- Rats, Wistar
- Tankyrases
(antagonists & inhibitors)
- Treatment Outcome
- Xenograft Model Antitumor Assays
|